US · Healthcare · Medical Devices
EPS came in at 3.52 against a street estimate of 3.56 — a miss of 1.1%.
Analysts rate Stryker Corporation a buy (23 buy, 7 hold, 0 sell out of 30) with an average price target of $340.48.
MIXED Stryker delivered solid growth and margin expansion, but weaker hip-and-knee demand, execution issues and vascular disruption prompted lower full-year guidance. Q3 FY26 U.S. growth was led by MedSurg and Neurotechnology, while international growth was broad and led by Australia, Germany, Canada and India. Analysts focused on the orthopedic slowdown, 2027 growth potential, CMR, vascular recovery and capital demand. Management attributed weakness to market conditions plus execution disruption, while emphasizing strong demand elsewhere and margin discipline. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.15% |
| Vanguard Capital Management, LLC | 5.88% |
| JPMorgan Chase & Co | 4.50% |
| State Street Corp | 4.05% |
| Greenleaf Trust | 3.97% |
| T. Rowe Price Associates, Inc. | 3.11% |
| Vanguard Portfolio Management, LLC | 2.13% |
| Wellington Management Company LLP | 2.13% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales rose to $6,520 million from $6,057 million, an increase of approximately 8%. • Nine-month net sales | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales increased 7.7% to $6.5 billion, with organic net sales also up 7.7%. • Adjusted operating income mar | 2026-10-29 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Stryker announced a planned CEO transition effective January 1, 2027. • Spencer S. Stiles, currently President and Chief Operatin | 2026-10-06 |
| Quarterly report · Q2 2026 STRYKER CORPORATION - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net sales (6 months 2026): $12,609 million vs. $11,8 | 2026-07-31 |
| Results announced · Q3 2026 STRYKER CORPORATION Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net sales: $6.6 billion, up 9.4% reported, 9.0% organic • Reported EPS: $3.30, up 44 | 2026-07-30 |
| Company announcement · Q2 2026 STRYKER CORPORATION FORM 8-K SUMMARY (JUNE 26, 2026) BUSINESS & SEGMENT HIGHLIGHTS • Stryker announced organizational restructuring in Q1 2026, crea | 2026-06-26 |
| Board / officer change · Q2 2026 STRYKER CORPORATION (SYK) – 8-K FILING SUMMARY HEADLINE NUMBERS • Leadership transition effective September 1, 2026: William E. Berry Jr. retiring a | 2026-05-20 |
| Quarterly report · Q1 2026 STRYKER CORPORATION – Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Net sales: $6,020 million (Q1 2026) vs $5,866 million (Q1 2025) – up 2.6% • Net e | 2026-05-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.88 / share ex-date Sep 30, 2026 · pay Oct 30, 2026 | 2026-09-30 |
| Dividend | $0.88 / share ex-date Jun 30, 2026 · pay Jul 31, 2026 | 2026-06-30 |
| Dividend | $0.88 / share ex-date Mar 31, 2026 · pay Apr 30, 2026 | 2026-03-31 |
| Dividend | $0.88 / share ex-date Dec 31, 2025 · pay Jan 30, 2026 | 2025-12-31 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Stryker Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.